Looking back moves patient care forward

See all 50 of our 2016 new and enhanced tests

See the list

Comprehensive Sarcoma Dx

Learn more about our Sarcoma Fusion Profiles
with NGS & FISH

Ewing – Non-Ewing – Pediatric Sarcoma
Rhabdomyosarcoma – Liposarcoma

Learn more

No pain. All the gain.

Biopsy-free NeoLAB™ Prostate

An innovative, non-invasive liquid biopsy 
test that uses biomarkers in blood and urine,
to assess prostate cancer risk

Learn more

GE Healthcare Biopharma Services

Pharma Services

NeoGenomics offers lab services for oncology clinical trials

Learn more 
Clarient

Clarient Client Resources

For current Clarient clients only, access your Clarient resources here.

Browse Resources

News

cervical-cancer-awareness-month

It’s Cervical Cancer
Awareness Month

View Our Innovative Cervical Cancer Tests

NeoGenomics Laboratories
is certified by the

Children’s Oncology Group

Learn more

Image%20Alt%20Text

HER-2 Breast FISH Alternative Assessment

The January-June 2017 self-assessment for our tech-only FISH clients is ready.

Sign into NeoUniversity™

View our ASH 2016 Posters

Flow in MDS

cfDNA in aplastic anemiaIDH1/2 in AML/MDSScreening with cfDNARead now
Image%20Alt%20Text

PD-L1 Overview

22C3, 28-8, and SP142

Learn more

New Tests

Targeted next-gen sequencing of clinically relevant mutations in angioimmunoblastic and peripheral T-cell lymphomas

Learn more

NeoTYPE™ AITL/Peripheral T-Cell Lymphoma Profile

Targeted sequencing to detect polymorphisms associated with prostate cancer resistance to androgen-deprivation therapy (ADT)

Learn more

HSD3B1 Genotyping

NeoLABTM EGFR T790M
Liquid Biopsy

Learn more

Accurate and sensitive detection of the EGFR T790M mutation using cell-free plasma DNA

IgH Clonality/MRD by NGS

Quantitative detection of B-lymphocyte clones and heterogeneity suitable for minimal residual disease (MRD) monitoring

Learn more

Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.

Indicated as an aid in identifying patients most likely to benefit from TECENTRIQ®

PD-L1, 142 (FDA) TECENTRIQ®

Learn more

Targeted next-gen sequencing panel that detects significant translocations in the genes NTRK1, NTRK3, and RET

Learn more

NGS Thyroid Fusion Profile